64 results about "Plasma derived" patented technology

This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.

The invention relates to a method for manufacturing an anti-RhD recombinant polyclonal antibody composition (anti-RhD rpAb). The method comprises obtaining a collection of cells transfected with a library of anti-RhD antibody expression vectors, wherein each cell in the collection is capable of expressing from a VH and VL comprising nucleic acid segment, one member of the library, which encodes a distinct member of anti-RhD recombinant polyclonal antibody composition and which is located at the same site in the genome of individual cells in said collection. The cells are cultured under suitable conditions for expression of the recombinant polyclonal antibody, which is obtained from the cells or culture supernatant. The nucleic acid segments encoding the anti-RhD rpAb is introduced into the cells by transfection with a library of vectors for site-specific integration. The present method is suitable for manufacturing anti-RhD rpAb, thereby making available a superior replacement of plasma-derived prophylactic and therapeutic immonoglobulin products.

The invention relates to a method for manufacturing a recombinant polyclonal protein composition, in particular a recombinant polyclonal antibody composition. The method comprises obtaining a collection of cells transfected with a library of variant nucleic acid sequences, wherein each cell in the collection is transfected with and capable of expressing one member of the library, which encodes a distinct member of a polyclonal protein that binds a particular antigen and which is located at the same single site in the genome of individual cells in said collection, wherein said nucleic acid sequence is not naturally associated with said cell in the collection. The cells are cultured under suitable conditions for expression of the polyclonal protein, which is obtained from the cells or culture supernatant. The nucleic acid sequence id introduced into the cells by transfection with a library of vectors for site-specific integration. The present method is suitable for manufacturing recombinant polyclonal antibodies, thereby mailing available a superior replacement of plasma-derived therapeutic immunoglobulin products.

The invention discloses a combination marker used for liver cancer detection and application thereof. The combination marker used for liver cancer detection comprises the respective methylation levelsof adenylate kinase 055957 (AK055957), 3-hydroxybutyrate dehydrogenase 1 (BDH1), chromosome 6 open reading frame 223 (C6orf223), disabled homolog 2-interacting protein (DAB2IP), human coagulation factor XII (F12), Golgi reassembly stacking protein (GRASP), leucine-rich repeat-containing protein 4 (LRRC4), nuclear factor I/X (NFIX), 5-oxoprolinase (ATP-hydrolysing) (OPLAH), recombinant protein tyrosine phosphatase F interacting protein 1 (PPFIA1), Pleckstrin homology and SEC7 domain-containing protein 4 (PSD4) and T-box 15 (TBX15). Experiments prove that whether the genome DNA or plasma circulating free DNA (cfDNA) of to-be-detected liver tissue comes from patients with liver cancer or patients without liver cancer can be judged by detecting the combination marker, and accuracy is relatively high; and the combination marker has significant application value.

A silicon sputter target is arranged in a silicon dot forming chamber, and a silicon dot formation target substrate is arranged in the chamber. Plasma is formed from a sputtering gas (typically a hydrogen gas) supplied into the chamber, and chemical sputtering is effected on the target with the plasma thus formed to form silicon dots on the substrate S. Optionally, with the plasma formed from a hydrogen gas and a silane-containing gas at a plasma emission intensity ratio (Si(288 nm)/Hβ) of 10.0 or lower, the silicon dots are formed on the substrate S. The silicon dots are terminally treated with the plasma derived from a terminally treating gas such as an oxygen gas.

An organic-inorganic hybrid film is deposited on a substrate by introducing, into a vacuum chamber, a gas mixture of a silicon alkoxide and an organic compound and generating a plasma derived from the gas mixture. Then, a hydrogen plasma process is performed with respect to the organic-inorganic hybrid film by introducing, into the vacuum chamber, a gas containing a reducing gas and generating a plasma derived from the gas. As a result, an organic component in the organic-inorganic hybrid film eliminates therefrom and numerous fine holes are formed in hollow portions from which the organic component has eliminated, whereby a porous film composed of the organic-inorganic hybrid film is obtained.

The invention relates to a method for manufacturing a recombinant polyclonal protein composition, in particular a recombinant polyclonal antibody composition. The method comprises obtaining a collection of cells transfected with a library of variant nucleic acid sequences, wherein each call in the collection is transfected with and capable of expressing one member of the library, which encodes a distinct member of a polyclonal protein that binds a particular antigen and which is located at the same single site in the genome of individual cells in said collection, wherein said nucleic acid sequence is not naturally associated with said cell in the collection. The cells are cultured under suitable conditions for expression of the polyclonal protein, which is obtained from the cells or culture supernatant. The nucleic acid sequence id introduced into the cells by transfection with a library of vectors for site-specific integration. The present method is suitable for manufacturing recombinant polyclonal antibodies, thereby making available a superior replacement of plasma-derived therapeutic immunoglobulin products.

The present invention relates to the use of a C1 inhibitor (C1INH) with shorter half-life than plasma-derived C1INH for the preparation of a medicament for the transient treatment of an individual. It relates to both therapeutic and prophylactic treatment. The method of the invention allows for the administration of C1INH at certain therapeutic levels for a concise pre-determined time span. Pharmaceutical compositions based on C1INH with shorter half-lives may be used both in situations where transient treatment is merely and advantage. The advantage of the use according to the invention is that an individual is not exposed to C1INH for longer than required, since the levels of the C1INH more rapidly subsides after administration has stopped. In contrast, levels of plasma-derived C1INH would remain elevated for a prolonged period of time.

The present invention provides, among other aspects, methods for the manufacture of plasma-derived immunoglobulin G compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-Aβ, anti-RAGE, and anti-α-synuclein antibodies). Advantageously, the methods provided do not affect the manufacturing processes or capabilities for producing plasma-derived IgG therapeutics. Plasma-derived IgG compositions that are highly enriched for anti-brain disease related protein antibodies (e.g., anti-Aβ, anti-RAGE, and anti-α-synuclein antibodies), as also provided here. Methods for the treatment of brain diseases and disorders by administration of plasma-derived IgG compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-Aβ, anti-RAGE, and anti-α-synuclein antibodies), are also provided.

The invention provides platelet-enriched plasma, as well as a preparation method and application thereof. According to the preparation method of the platelet-enriched plasma, the platelet-enriched plasma is prepared by taking medical waste white membrane layer cells as raw materials. Compared with the traditional preparation method of platelet-enriched plasma derived from whole blood, the preparation method of the platelet-enriched plasma has the advantages that the raw materials can be obtained cheaply and massively, so that preparation cost is greatly reduced and preparation scale is enlarge. In addition, the method provided by the invention integrates the steps of separating platelet-enriched plasma and activating platelet into one step, and the platelet-enriched plasma prepared by the method can be directly used.

The present invention provides methods of administering a clotting factor by a fixed dosing regimen; methods of reducing, ameliorating, or preventing one or more symptoms of a bleeding disease or disorder; and a kit comprising a dotting factor useful for a fixed dosing regimen. While plasma-derived and recombinant clotting factor products allow hemophilia patients to live longer and healthier, hemophilia still remains one of the most costly and complex conditions to manage.

The invention relates to a method for manufacturing a recombinant polyclonal protein composition, in particular a recombinant polyclonal antibody composition. The method comprises obtaining a collection of cells transfected with a library of variant nucleic acid sequences, wherein each cell in the collection is transfected with and capable of expressing one member of the library, which encodes a distinct member of a polyclonal protein that binds a particular antigen and which is located at the same single site in the genome of individual cells in said collection, wherein said nucleic acid sequence is not naturally associated with said cell in the collection. The cells are cultured under suitable conditions for expression of the polyclonal protein, which is obtained from the cells or culture supernatant. The nucleic acid sequence id introduced into the cells by transfection with a library of vectors for site-specific integration. The present method is suitable for manufacturing recombinant polyclonal antibodies, thereby making available a superior replacement of plasma-derived therapeutic immunoglobulin products.

The present invention provides methods for identifying candidate biomarkers in the plasma microparticle proteome. It also provides methods for isolating, identifying, and analyzing microparticles derived from plasma, particularly platelet-poor plasma.

The invention relates to an aged rat brain vascular endothelial cell culture fluid. On the basis of each 100 ml of DMEM (Dulbecco Modified Eagle Medium) culture medium, components including plasma derived serum (PDS), penicillin-streptomycin, L-glutamine, gentamicin, heparin, an alkaline fiber growth factor, an endothelial cell growth replenishing factor, vitamin C, a vascular endothelial growth factor, an insulin-like growth factor-1 and an endothelium growth factor are added. According to the aged rat brain vascular endothelial cell culture fluid, the PDS is adopted for replacing FBS (Fetal Bovine Serum), beef calf serum or horse serum in the traditional culture fluid to ensure that the purity of brain vascular endothelial cells is increased by 30 percent; and the vitamin C and puromycin are added to ensure that the brain vascular endothelial cells grow more rapidly and purely.

An ion-exchange chromatography support for reducing the ADAMTS13 amount present in a plasma-derived solution containing human von Willebrand factor. The support includes a large-pore, vinyl polymer-type resin bearing DEAE groups, and a buffer including trisodium citrate, sodium chloride, calcium chloride, glycine and lysine.

The present invention provides, among other things, methods and compositions for treating complement mediated disease. In some embodiments, recombinant human C1 esterase inhibitor proteins having similar or longer half-life than native plasma-derived human C1 esterase inhibitor, and methods of making the same are provided. In some embodiments, the invention provides a method for administering an effective amount of a recombinant human C1 esterase inhibitor protein to an individual who is suffering from or susceptible to a complement-mediated disease such that at least one symptom or feature of said complement-mediated disease is prevented and/or reduced in intensity, severity, or frequency.

The present invention provides, among other aspects, methods for the manufacture of plasma-derived immunoglobulin G compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-β, anti-RAGE, and anti-α-synuclein antibodies). Advantageously, the methods provided do not affect the manufacturing processes or capabilities for producing plasma-derived IgG therapeutics. Plasma-derived IgG compositions that are highly enriched for anti-brain disease related protein antibodies (e.g., anti-β, anti-RAGE, and anti-α-synuclein antibodies), as also provided here. Methods for the treatment of brain diseases and disorders by administration of plasma-derived IgG compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-β, anti-RAGE, and anti-α-synuclein antibodies), are also provided.

The present invention provides an antibody that binds to the surface antigen (HBsAg) of hepatitis B virus (HBV) to neutralize the hepatitis B virus. The surface antigen-binding site of the antibody was found to play a very important role in viral replication, and when a mutation in the site occurs, viral replication is significantly inhibited, and thus at least HBV virus cannot cause a mutation in the site.

In the present invention, it was confirmed by the use of patient-derived virus that the antibody of the present invention binds to either YMDD mutant hepatitis B virus, produced by conventional viral replication inhibitors, or G145R HBsAg mutants to which plasma-derived HBIG (hepatitis B immunoglobulin) does not bind.

In addition, the in vivo effect of the antibody of the present invention was examined using chimpanzees which are unique animal models for hepatitis B virus. As a result, it was found that the antibody has the effect of neutralizing even wild-type hepatitis B virus in the in vivo model. Thus, it can be seen that the antibody of the present invention has the ability to bind not only to wild-type hepatitis B virus, but also mutant hepatitis B viruses having a polymerase YMDD mutant and a surface antigen G145R mutation, as well as various mutant viruses derived from patients.

Thus, the antibody of the present invention can be effectively used for the prevention or treatment of infections with not only wild-type hepatitis B virus, but also mutant hepatitis B viruses.